ANTIBODY-CONTAINING PREPARATION

In one non-limiting embodiment, the present disclosure relates to lyophilized formulations containing an IL-31 antagonist (for example, an anti-IL-31RA antibody) as an active ingredient, the lyophilized formulations further containing arginine and/or a salt thereof and sucrose and/or trehalose. In a...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	SASAKI, Hitoshi, MURATA, Hiroko, YAMAGUCHI, So, KAMEOKA, Daisuke, NUMATA, Megumi, HIRONIWA, NAOKA, YOSHIZAWA, Toru
Format:	Patent
Sprache:	eng ; fre ; ger
Schlagworte:	CHEMISTRY HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PEPTIDES PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

container_end_page
container_issue
container_start_page
container_title
container_volume
creator	SASAKI, Hitoshi MURATA, Hiroko YAMAGUCHI, So KAMEOKA, Daisuke NUMATA, Megumi HIRONIWA, NAOKA YOSHIZAWA, Toru
description	In one non-limiting embodiment, the present disclosure relates to lyophilized formulations containing an IL-31 antagonist (for example, an anti-IL-31RA antibody) as an active ingredient, the lyophilized formulations further containing arginine and/or a salt thereof and sucrose and/or trehalose. In another non-limiting embodiment, the present disclosure relates to solution formulations containing an IL-31 antagonist as an active ingredient, the solution formulations further containing arginine and/or a salt thereof. In other non-limiting embodiments, the present disclosure relates to methods for stabilizing an antibody (for example, an anti-IL-31RA antibody) in an antibody-containing formulation, methods for suppressing antibody aggregation (aggregate formation) in an antibody-containing formulation, and methods for reducing components with charge heterogeneity in an antibody-containing formulation, the methods being characterized in that the formulation is prepared to contain arginine and/or a salt thereof, and/or sucrose and/or trehalose.
format	Patent
fullrecord	<record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_EP4062933A4</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>EP4062933A4</sourcerecordid><originalsourceid>FETCH-epo_espacenet_EP4062933A43</originalsourceid><addsrcrecordid>eNrjZJB39AvxdPJ3idR19vcLcfT08_RzVwgIcg1wDHIM8fT342FgTUvMKU7lhdLcDApuriHOHrqpBfnxqcUFicmpeakl8a4BJgZmRpbGxo4mxkQoAQCtlSGA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>ANTIBODY-CONTAINING PREPARATION</title><source>esp@cenet</source><creator>SASAKI, Hitoshi ; MURATA, Hiroko ; YAMAGUCHI, So ; KAMEOKA, Daisuke ; NUMATA, Megumi ; HIRONIWA, NAOKA ; YOSHIZAWA, Toru</creator><creatorcontrib>SASAKI, Hitoshi ; MURATA, Hiroko ; YAMAGUCHI, So ; KAMEOKA, Daisuke ; NUMATA, Megumi ; HIRONIWA, NAOKA ; YOSHIZAWA, Toru</creatorcontrib><description>In one non-limiting embodiment, the present disclosure relates to lyophilized formulations containing an IL-31 antagonist (for example, an anti-IL-31RA antibody) as an active ingredient, the lyophilized formulations further containing arginine and/or a salt thereof and sucrose and/or trehalose. In another non-limiting embodiment, the present disclosure relates to solution formulations containing an IL-31 antagonist as an active ingredient, the solution formulations further containing arginine and/or a salt thereof. In other non-limiting embodiments, the present disclosure relates to methods for stabilizing an antibody (for example, an anti-IL-31RA antibody) in an antibody-containing formulation, methods for suppressing antibody aggregation (aggregate formation) in an antibody-containing formulation, and methods for reducing components with charge heterogeneity in an antibody-containing formulation, the methods being characterized in that the formulation is prepared to contain arginine and/or a salt thereof, and/or sucrose and/or trehalose.</description><language>eng ; fre ; ger</language><subject>CHEMISTRY ; HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; ORGANIC CHEMISTRY ; PEPTIDES ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><creationdate>2023</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20231213&DB=EPODOC&CC=EP&NR=4062933A4$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,780,885,25562,76317</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20231213&DB=EPODOC&CC=EP&NR=4062933A4$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>SASAKI, Hitoshi</creatorcontrib><creatorcontrib>MURATA, Hiroko</creatorcontrib><creatorcontrib>YAMAGUCHI, So</creatorcontrib><creatorcontrib>KAMEOKA, Daisuke</creatorcontrib><creatorcontrib>NUMATA, Megumi</creatorcontrib><creatorcontrib>HIRONIWA, NAOKA</creatorcontrib><creatorcontrib>YOSHIZAWA, Toru</creatorcontrib><title>ANTIBODY-CONTAINING PREPARATION</title><description>In one non-limiting embodiment, the present disclosure relates to lyophilized formulations containing an IL-31 antagonist (for example, an anti-IL-31RA antibody) as an active ingredient, the lyophilized formulations further containing arginine and/or a salt thereof and sucrose and/or trehalose. In another non-limiting embodiment, the present disclosure relates to solution formulations containing an IL-31 antagonist as an active ingredient, the solution formulations further containing arginine and/or a salt thereof. In other non-limiting embodiments, the present disclosure relates to methods for stabilizing an antibody (for example, an anti-IL-31RA antibody) in an antibody-containing formulation, methods for suppressing antibody aggregation (aggregate formation) in an antibody-containing formulation, and methods for reducing components with charge heterogeneity in an antibody-containing formulation, the methods being characterized in that the formulation is prepared to contain arginine and/or a salt thereof, and/or sucrose and/or trehalose.</description><subject>CHEMISTRY</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>ORGANIC CHEMISTRY</subject><subject>PEPTIDES</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2023</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZJB39AvxdPJ3idR19vcLcfT08_RzVwgIcg1wDHIM8fT342FgTUvMKU7lhdLcDApuriHOHrqpBfnxqcUFicmpeakl8a4BJgZmRpbGxo4mxkQoAQCtlSGA</recordid><startdate>20231213</startdate><enddate>20231213</enddate><creator>SASAKI, Hitoshi</creator><creator>MURATA, Hiroko</creator><creator>YAMAGUCHI, So</creator><creator>KAMEOKA, Daisuke</creator><creator>NUMATA, Megumi</creator><creator>HIRONIWA, NAOKA</creator><creator>YOSHIZAWA, Toru</creator><scope>EVB</scope></search><sort><creationdate>20231213</creationdate><title>ANTIBODY-CONTAINING PREPARATION</title><author>SASAKI, Hitoshi ; MURATA, Hiroko ; YAMAGUCHI, So ; KAMEOKA, Daisuke ; NUMATA, Megumi ; HIRONIWA, NAOKA ; YOSHIZAWA, Toru</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_EP4062933A43</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng ; fre ; ger</language><creationdate>2023</creationdate><topic>CHEMISTRY</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>ORGANIC CHEMISTRY</topic><topic>PEPTIDES</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><toplevel>online_resources</toplevel><creatorcontrib>SASAKI, Hitoshi</creatorcontrib><creatorcontrib>MURATA, Hiroko</creatorcontrib><creatorcontrib>YAMAGUCHI, So</creatorcontrib><creatorcontrib>KAMEOKA, Daisuke</creatorcontrib><creatorcontrib>NUMATA, Megumi</creatorcontrib><creatorcontrib>HIRONIWA, NAOKA</creatorcontrib><creatorcontrib>YOSHIZAWA, Toru</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>SASAKI, Hitoshi</au><au>MURATA, Hiroko</au><au>YAMAGUCHI, So</au><au>KAMEOKA, Daisuke</au><au>NUMATA, Megumi</au><au>HIRONIWA, NAOKA</au><au>YOSHIZAWA, Toru</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>ANTIBODY-CONTAINING PREPARATION</title><date>2023-12-13</date><risdate>2023</risdate><abstract>In one non-limiting embodiment, the present disclosure relates to lyophilized formulations containing an IL-31 antagonist (for example, an anti-IL-31RA antibody) as an active ingredient, the lyophilized formulations further containing arginine and/or a salt thereof and sucrose and/or trehalose. In another non-limiting embodiment, the present disclosure relates to solution formulations containing an IL-31 antagonist as an active ingredient, the solution formulations further containing arginine and/or a salt thereof. In other non-limiting embodiments, the present disclosure relates to methods for stabilizing an antibody (for example, an anti-IL-31RA antibody) in an antibody-containing formulation, methods for suppressing antibody aggregation (aggregate formation) in an antibody-containing formulation, and methods for reducing components with charge heterogeneity in an antibody-containing formulation, the methods being characterized in that the formulation is prepared to contain arginine and/or a salt thereof, and/or sucrose and/or trehalose.</abstract><oa>free_for_read</oa></addata></record>
fulltext	fulltext_linktorsrc
identifier
ispartof
issn
language	eng ; fre ; ger
recordid	cdi_epo_espacenet_EP4062933A4
source	esp@cenet
subjects	CHEMISTRY HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PEPTIDES PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
title	ANTIBODY-CONTAINING PREPARATION
url	https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-09T12%3A37%3A28IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=SASAKI,%20Hitoshi&rft.date=2023-12-13&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EEP4062933A4%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true